A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorVanda Pharmaceuticals
About this trial
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
Eligibility criteria
Qualifiers
Body Mass Index ≥ 25 and < 40 kg/m²
No serious medical problems or chronic diseases, specifically no type I or type II diabetes
Disqualifiers
Another disorder that contributes to gastrointestinal symptoms
History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
Exposure to any investigational medication within the past 60 days
Trial design
Treatments tested in this trial
- Tradipitant
- Placebo
Treatment groups
280 Participants
are divided into 2 treatment groupsLocations
10California
Vanda Investigational Site90025, Los Angeles United States
Vanda Investigational Site92108, San Diego United States
Vanda Investigational Site95124, San Jose United States
Florida
Vanda Investigational Site33613, Tampa United States
Sponsors and collaborators
Vanda Pharmaceuticals
Lead sponsor
Source ClinicalTrials.gov